osimertinib
astrazeneca
['adaura', 'nsclc', 'sclc', 'osimertinib', 'aura ,(-laura)']
interesting review by at #asco23 about adaura study that is the first global phase iii to demonstrate a statistically significant dfs and os benefit with adjuvant osimertinib vs placebo in pts with egfrm stage ib iiia nsclc 
Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla. Cancer treatment must be personalized to the individual needs of the patient.